anixa.com (ANIX) - Cash per Share

Corporate emblem and logo of Anixa Biosciences, Inc. (ANIX)

The disciplined management of Anixa Biosciences, Inc. (ANIX) effectively manages capital, protecting shareholder stakes from dilution. The cash per share calculation confirms this approach, as the metric remains around 0.40. The development of breast cancer drugs relies on automated substance synthesis. Meanwhile, Anixa Biosciences, Inc. (ANIX) grows its assets organically through institutional partnerships, planning for product licensing.

Anixa Biosciences (ANIX) - Cash per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for Anixa Biosciences, Inc.

- cash position and cash flow details:
Comprehensive company analysis:Anixa Biosciences, Inc.
Manufactured product of Anixa Biosciences Inc

For the biotech sector, Anixa Biosciences, Inc. (ANIX) depends critically on the efficiency of liquidity spending on clinical trials while maintaining intellectual property protection. This indicator calculates the net cash position per share; therefore, the cash per share history allows for an assessment of the risk of a liquidity gap or excessive capital freezing, confirming management's discipline in preventing shareholder dilution.